WASHINGTON - In the first settlement of a state and federal investigation of drug-industry pricing practices, a US unit of Bayer AG has tentatively agreed to pay $14 million to resolve allegations that it caused Medicaid to overpay for its drugs. Bayer, which has confirmed a settlement, has not admitted wrongdoing. The settlement requires that the company report more accurate price information for all of its drugs to state and federal regulators. In addition, the company must cooperate with continuing investigation.
More than 20 drug companies are under current investigation, including Abbott Laboratories, Bristol-Myers Squibb Co., Glaxo Wellcome PLC's US unit, and SmithKline Beecham PLC. All companies have denied any wrongdoing. For more information visit www.hcfa.gov/medicaid.
Gag Order Puts Public Health at Risk, APIC Urges Immediate Action
February 4th 2025APIC warns that the HHS gag order on CDC communications endangers public health, delaying critical infection updates and weakening outbreak response amid rising tuberculosis, avian flu, Ebola, and measles threats.
Breaking Barriers: The Future of HIV Prevention and the Fight for Widespread PrEP Access
January 31st 2025Despite medical advances, HIV prevention faces roadblocks—low PrEP adoption, stigma, and accessibility issues threaten progress. Experts push for innovative, long-acting solutions to end the epidemic.
The Hidden Dangers of Hospital Ventilation: Are We Spreading Viruses Further?
January 31st 2025New research reveals hospital ventilation and air purifiers may unintentionally spread viral particles, increasing infection risks. Infection preventionists must rethink airflow strategies to protect patients and staff.